Technological and Patent Evolution of Murine Monoclonal Antibodies
Journal Title: Journal of Advances in Biology & Biotechnology - Year 2017, Vol 14, Issue 2
Abstract
Among the pharmaceutical products targeted for patent protection, monoclonal antibodies stand out. Technological advances involving monoclonal antibodies aim to minimize detrimental human immune responses to antibodies (e.g., human anti-murine antibodies [HAMA]) and increase the binding affinity of antibodies to their antigen, making them more specific for their therapeutic target. This work evaluates the main technological advances pertaining to monoclonal antibodies, from the creation of technology for the immortalization of cells to generate hybridomas through the generation of chimeric and humanized antibodies by genetic engineering techniques, phage display technology, and transgenic mice. It also aims to provide an overview of commercially available and patented murine monoclonal antibodies and to correlate the main players, markets, and therapeutic uses for which the antibodies were developed. The study of mMAB (murine monoclonal antibodies) proved to be of great importance to understand how the development of these antibodies and their protection by patents affects their therapeutic use in cancer patients, in diagnostics, to treat inflammation, etc. The United States (US), Japan (JP), France (FR), and China (CN) constitute potential markets for these protected technological advances. Among current usage trends of three murine monoclonal antibodies whose patents have expired, the use of generic and/or biosimilar is evidenced, as well as the use of these assets to guarantee the protection of new products, new associated processes (e.g., new combinations, associations, or dosage forms), or new processes. The newest market trends related to patent protection in this technological area incorporate the use of monoclonal antibody fragments.
Authors and Affiliations
Kátia dos Reis, José Procópio Moreno Senna, Nei Pereira Júnior, Maria Antonieta Peixoto Gimenes Couto
Keywords
Related Articles
- EP ID EP318148
- DOI 10.9734/JABB/2017/34759
- Views 94
- Downloads 0
Analyses of Trypanosoma brucei Phospholipase A2 Structure and Function Using Bioinformatics Approach
Aim: Studying Phospholipase A2 is increasingly needful because of the enzyme’s biotechnological potentials and involvement in the pathogenicity of Trypanosoma species. This work was therefore designed to study some of t...
Bio-ethanol Production as Bio-solvent (Antifermenter), Antiseptic and Bio-fuel from Date Fruit Waste and its Suitable Properties Identification
Significance of the Study: Biomass derived bio-ethanol is biodegradable, nontoxic and suitable substitute for fossil fuels. It can be used as bio-solvent and antiseptic in the pharmaceutical industry and can also be used...
Statistical Optimization of Alkaline Protease Production Using Isolated Strain by Submerged Fermentation
Aim: Optimization of alkaline protease production using a newly isolated strain Alternaria sp. by submerged fermentation. The production of inexpensive proteolytic enzymes not only solves environmental problems, but also...
Growth Patterns and Degradative Potentials of Pseudomonas sp. Isolated from Waste Dumpsite Soil in Crude Oil Supplemented Soil Extract and Mineral Salts Media
Introduction: Pollution caused by crude oil and its products is the most prevalent and widespread problem in soil and water environments and is increasingly being implicated as being responsible for the global warming me...
Delimitation of the Pore in Tweety Homolog 1 Channels: A Model-guided Approach
Tweety homolog proteins have been indicated as ´putative anion channels´, but yet there is some lack of definitive data in this regard. Here, we focused on the human Tweety homolog 1 protein (hTTYH1), and elaborated a mo...